Cargando…
Characterizing Tyrosine Phosphorylation Signaling in Lung Cancer Using SH2 Profiling
BACKGROUND: Tyrosine kinases drive the proliferation and survival of many human cancers. Thus profiling the global state of tyrosine phosphorylation of a tumor is likely to provide a wealth of information that can be used to classify tumors for prognosis and prediction. However, the comprehensive an...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957407/ https://www.ncbi.nlm.nih.gov/pubmed/20976048 http://dx.doi.org/10.1371/journal.pone.0013470 |
_version_ | 1782188229021138944 |
---|---|
author | Machida, Kazuya Eschrich, Steven Li, Jiannong Bai, Yun Koomen, John Mayer, Bruce J. Haura, Eric B. |
author_facet | Machida, Kazuya Eschrich, Steven Li, Jiannong Bai, Yun Koomen, John Mayer, Bruce J. Haura, Eric B. |
author_sort | Machida, Kazuya |
collection | PubMed |
description | BACKGROUND: Tyrosine kinases drive the proliferation and survival of many human cancers. Thus profiling the global state of tyrosine phosphorylation of a tumor is likely to provide a wealth of information that can be used to classify tumors for prognosis and prediction. However, the comprehensive analysis of tyrosine phosphorylation of large numbers of human cancer specimens is technically challenging using current methods. METHODOLOGY/PRINCIPAL FINDINGS: We used a phosphoproteomic method termed SH2 profiling to characterize the global state of phosphotyrosine (pTyr) signaling in human lung cancer cell lines. This method quantifies the phosphorylated binding sites for SH2 domains, which are used by cells to respond to changes in pTyr during signaling. Cells could be grouped based on SH2 binding patterns, with some clusters correlated with EGF receptor (EGFR) or K-RAS mutation status. Binding of specific SH2 domains, most prominently RAS pathway activators Grb2 and ShcA, correlated with EGFR mutation and sensitivity to the EGFR inhibitor erlotinib. SH2 binding patterns also reflected MET activation and could identify cells driven by multiple kinases. The pTyr responses of cells treated with kinase inhibitors provided evidence of distinct mechanisms of inhibition. CONCLUSIONS/SIGNIFICANCE: This study illustrates the potential of modular protein domains and their proteomic binding profiles as powerful molecular diagnostic tools for tumor classification and biomarker identification. |
format | Text |
id | pubmed-2957407 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-29574072010-10-25 Characterizing Tyrosine Phosphorylation Signaling in Lung Cancer Using SH2 Profiling Machida, Kazuya Eschrich, Steven Li, Jiannong Bai, Yun Koomen, John Mayer, Bruce J. Haura, Eric B. PLoS One Research Article BACKGROUND: Tyrosine kinases drive the proliferation and survival of many human cancers. Thus profiling the global state of tyrosine phosphorylation of a tumor is likely to provide a wealth of information that can be used to classify tumors for prognosis and prediction. However, the comprehensive analysis of tyrosine phosphorylation of large numbers of human cancer specimens is technically challenging using current methods. METHODOLOGY/PRINCIPAL FINDINGS: We used a phosphoproteomic method termed SH2 profiling to characterize the global state of phosphotyrosine (pTyr) signaling in human lung cancer cell lines. This method quantifies the phosphorylated binding sites for SH2 domains, which are used by cells to respond to changes in pTyr during signaling. Cells could be grouped based on SH2 binding patterns, with some clusters correlated with EGF receptor (EGFR) or K-RAS mutation status. Binding of specific SH2 domains, most prominently RAS pathway activators Grb2 and ShcA, correlated with EGFR mutation and sensitivity to the EGFR inhibitor erlotinib. SH2 binding patterns also reflected MET activation and could identify cells driven by multiple kinases. The pTyr responses of cells treated with kinase inhibitors provided evidence of distinct mechanisms of inhibition. CONCLUSIONS/SIGNIFICANCE: This study illustrates the potential of modular protein domains and their proteomic binding profiles as powerful molecular diagnostic tools for tumor classification and biomarker identification. Public Library of Science 2010-10-19 /pmc/articles/PMC2957407/ /pubmed/20976048 http://dx.doi.org/10.1371/journal.pone.0013470 Text en Machida et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Machida, Kazuya Eschrich, Steven Li, Jiannong Bai, Yun Koomen, John Mayer, Bruce J. Haura, Eric B. Characterizing Tyrosine Phosphorylation Signaling in Lung Cancer Using SH2 Profiling |
title | Characterizing Tyrosine Phosphorylation Signaling in Lung Cancer Using SH2 Profiling |
title_full | Characterizing Tyrosine Phosphorylation Signaling in Lung Cancer Using SH2 Profiling |
title_fullStr | Characterizing Tyrosine Phosphorylation Signaling in Lung Cancer Using SH2 Profiling |
title_full_unstemmed | Characterizing Tyrosine Phosphorylation Signaling in Lung Cancer Using SH2 Profiling |
title_short | Characterizing Tyrosine Phosphorylation Signaling in Lung Cancer Using SH2 Profiling |
title_sort | characterizing tyrosine phosphorylation signaling in lung cancer using sh2 profiling |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957407/ https://www.ncbi.nlm.nih.gov/pubmed/20976048 http://dx.doi.org/10.1371/journal.pone.0013470 |
work_keys_str_mv | AT machidakazuya characterizingtyrosinephosphorylationsignalinginlungcancerusingsh2profiling AT eschrichsteven characterizingtyrosinephosphorylationsignalinginlungcancerusingsh2profiling AT lijiannong characterizingtyrosinephosphorylationsignalinginlungcancerusingsh2profiling AT baiyun characterizingtyrosinephosphorylationsignalinginlungcancerusingsh2profiling AT koomenjohn characterizingtyrosinephosphorylationsignalinginlungcancerusingsh2profiling AT mayerbrucej characterizingtyrosinephosphorylationsignalinginlungcancerusingsh2profiling AT hauraericb characterizingtyrosinephosphorylationsignalinginlungcancerusingsh2profiling |